Journal article
Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer
Abstract
Triple negative breast cancer (TNBC) is an aggressive subtype of the disease with poor clinical outcomes and limited therapeutic options. Immune checkpoint blockade (CP) has surged to the forefront of cancer therapies with widespread clinical success in a variety of cancer types. However, the percentage of TNBC patients that benefit from CP as a monotherapy is low, and clinical trials have shown the need for combined therapeutic modalities. …
Authors
Vito A; Rathmann S; Mercanti N; El-Sayes N; Mossman K; Valliant J
Journal
International Journal of Molecular Sciences, Vol. 22, No. 9,
Publisher
MDPI
DOI
10.3390/ijms22094843
ISSN
1661-6596